CA Patent

CA2629443C — Oxygen linked pyrimidine derivatives

Assigned to CTI Biopharma Corp · Expires 2016-12-13 · 9y expired

What this patent protects

The present invention relates to pyrimidine compounds of Formula (I) that are useful as anti-proliferative agents. (see Formula I)

USPTO Abstract

The present invention relates to pyrimidine compounds of Formula (I) that are useful as anti-proliferative agents. (see Formula I)

Drugs covered by this patent

pacritinib-citrate (PACRITINIB CITRATE)

Patent Metadata

Patent number: CA2629443C
Jurisdiction: CA
Classification: —
Expires: 2016-12-13
Drug substance claim: No
Drug product claim: No
Assignee: CTI Biopharma Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.